Since the release of the first glucagon-like peptide-1 (GLP-1) receptor agonist exenatide almost two decades ago, there has been an increased interest in the use of this medication class not only for the treatment of type 2 diabetes and obesity, but also to reduce risk in other cardiometabolic disease states such as MASLD and MASH. The gene discussed is GLP1R; the disease is Obesity.